Form 4: Insider Sells Werewolf Therapeutics Shares

Ansbert Gadicke and affiliated entities reported the sale of Werewolf Therapeutics common stock totaling 209,652 shares over three days in November 2025.

Summary

• Ansbert Gadicke, a Director and 10% owner of Werewolf Therapeutics, Inc., along with several affiliated MPM entities, reported sales of common stock.
• A total of 209,652 shares were sold across three separate transactions between November 13 and November 17, 2025.
• On November 13, 2025, 90,951 shares were sold at a weighted average price of $0.98.
• On November 14, 2025, 61,640 shares were sold at a weighted average price of $0.93.
• On November 17, 2025, 57,061 shares were sold at a weighted average price of $0.95.
• All transactions were conducted under a Rule 10b5-1 trading plan established on September 24, 2025.
• Following these transactions, the indirect beneficial ownership of the reporting persons stands at 5,481,539 shares.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to significant insider sales, even though they are under a 10b5-1 plan. While pre-scheduled, large sales by a director and 10% owner can still be perceived by the market as a lack of conviction or a move to diversify, especially at relatively low share prices. The routine nature of 10b5-1 plans prevents a lower score, but the volume of sales warrants caution.

Negatives

• Significant sales by a director and 10% owner, Ansbert Gadicke, and affiliated entities, totaling 209,652 shares.
• The sales occurred at prices ranging from $0.918 to $1.07, which are relatively low share prices.

Future Outlook

NA

Management Comments

• The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

Industry Context

This Form 4 filing reports routine insider sales under a pre-established 10b5-1 plan, which is a common practice for executives and large shareholders to manage their equity holdings without being accused of trading on material non-public information. It does not provide specific insights into broader industry trends for biotechnology or oncology, but such sales are often monitored by investors for sentiment.

Stakeholder Impact

• Shareholders: May interpret the sales as a negative signal, potentially leading to downward pressure on the stock price, despite the 10b5-1 plan.
• Management/Employees: No direct impact mentioned, but a decline in stock price could affect equity-based compensation.

Key Dates

Recommendation

While the insider sales are substantial, they were executed under a pre-established 10b5-1 plan, which suggests they are not a reaction to new, negative material information. However, significant sales by a director and 10% owner, even if planned, can still create negative market sentiment and put pressure on the stock. Given the lack of other operational or financial updates in this filing, a 'hold' recommendation is appropriate, advising investors to monitor future company developments and market reaction rather than making immediate buy or sell decisions based solely on these planned insider sales.

Keywords

Werewolf Therapeutics, HOWL, SEC Form 4, Insider Trading, Stock Sale, Ansbert Gadicke, MPM BioImpact, 10b5-1 Plan, Biotechnology, Oncology